Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7707 results

  1. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development [GID-TA10607] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued [GID-TAG410]

    Technology appraisal guidance
    Discontinued

  3. Prasterone for the treatment of systemic lupus erythematosus [ID392]

    Discontinued [GID-TAG373]

    Technology appraisal guidance
    Discontinued

  4. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued [GID-TAG391]

    Technology appraisal guidance
    Discontinued

  5. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued [GID-TAG330]

    Technology appraisal guidance
    Discontinued

  6. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

    Technology appraisal guidance
    Discontinued

  7. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued [GID-TAG395]

    Technology appraisal guidance
    Discontinued

  8. Venous leg ulcers - new treatments [ID394]

    Discontinued [GID-TAG370]

    Technology appraisal guidance
    Discontinued

  9. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued [GID-TAG378]

    Technology appraisal guidance
    Discontinued

  10. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued [GID-TAG390]

    Technology appraisal guidance
    Discontinued

  11. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued [GID-TAG396]

    Technology appraisal guidance
    Discontinued

  12. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued [GID-TAG399]

    Technology appraisal guidance
    Discontinued

  13. Thrombophilia [ID393]

    Discontinued [GID-TAG374]

    Technology appraisal guidance
    Discontinued

  14. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  15. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued